Sologub T V, Romantsov M G, Rybalkina T S, Rybalkin S B, Smagina A N, Isakov V A, Kovalenko A L
Klin Med (Mosk). 2011;89(3):54-7.
The study demonstrates a higher pharmacotherapeutic and economic efficacy of an alternative treatment modality for genital herpes using cycloferon, an inducer of endogenous interferons, compared with acyclovir. Clinical remission due to suppression of virus replication occurred in 72.3 and 73.5% of the cases within 6 months after the treatment with cycloferon and cycloferon + acyclovir respectively. Acyclovir alone prevented reactivation of the disease only in 128% of the patients. The cost/effectiveness ratio in patients given combined therapy was 27.95 compared with 12.9 in case of monotherapy with acyclovir which suggests economic feasibility of the use of cycloferon as the drug of choice for the management of genital herpes. The efficacy of therapy was identical in patients with and without deletion of the GSTM1 gene encoding glutathione-S-transferase which suggests the possibility to effectively use cycloferon in genetically heterogeneous patients.
该研究表明，与阿昔洛韦相比，使用内源性干扰素诱导剂环孢素治疗生殖器疱疹的替代治疗方式具有更高的药物治疗和经济疗效。分别用环孢素和环孢素+阿昔洛韦治疗后6个月内，72.3%和73.5%的病例因病毒复制受抑制而出现临床缓解。仅使用阿昔洛韦时，仅12.8%的患者病情未复发。联合治疗患者的成本效益比为27.95，而阿昔洛韦单药治疗的成本效益比为12.9，这表明使用环孢素作为生殖器疱疹治疗的首选药物在经济上是可行的。编码谷胱甘肽-S-转移酶的GSTM1基因缺失和未缺失的患者治疗效果相同，这表明在基因异质性患者中有效使用环孢素是可能的。
